Market Cap 82.12M
Revenue (ttm) 0.00
Net Income (ttm) -138.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,667,500
Avg Vol 1,832,302
Day's Range N/A - N/A
Shares Out 59.51M
Stochastic %K 32%
Beta -0.12
Analysts Strong Sell
Price Target $7.83

Company Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle con...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 980 9099
Address:
1599 Industrial Road, San Carlos, United States
nf04
nf04 Oct. 24 at 7:34 PM
$BMEA https://www.wsj.com/market-data/quotes/BMEA/company-people/executive-profile/53552593; https://www.investing.com/equities/pharmacyclics-chart; with all the blame against the management, most seem to forget what about absolute veterans sit at the helm of Biomea; Erdtmann (Pharmacyclics, Ibrutinib, blockbuster in CLL) and Hitchcock (Gilead) were involved in two of the biggest ever Biotech growth stories. They also seem to have taken inspiration of Duggan's approach at Pharmacyclics regarding minimal direct compensation, I think the upcoming earnings report will come in as a decent catalyst.
1 · Reply
BobBijawklah
BobBijawklah Oct. 24 at 7:18 PM
$BMEA light the match
0 · Reply
bet_on_biotechs
bet_on_biotechs Oct. 24 at 6:31 PM
$BMEA Someone told me to take a look here... I did...attending a funeral would have been more fun... Conclusion: The lies here are so high that the beams bend and I wondered why some people are typing their fingers to the bone when nothing is expected in the next few years. Kind of strange... If I were interested, I would think about why that is...just a side note. Short visit ended - nice weekend.
0 · Reply
BobBijawklah
BobBijawklah Oct. 24 at 6:01 PM
$BMEA three years from now mark my previous post and you will be saying marty ....
0 · Reply
BobBijawklah
BobBijawklah Oct. 24 at 5:59 PM
$BMEA Icovamenib was a cancer drug at first. VIagra was a high blood pressure drug at first. All drugs are hypothesis driven . So you must follow the data. hedge funds viewed the data in a narrow lens. td failed to meet the anticipated threshold MNGT was then basing their new trial plans off of a small % of the trial participants based on their anaylsis. Given the need for more raises it became to risky for some and they reversed positions and shorted. Now From all models pre clinical to early clinical the drug has performed the same . So when they complete the bigger trials of SIDD and Ozempic plus that data will bring the stock back to levels pre drop . So buying now is smart because they have enough cash to get to that data. Once they do they will do an offering to advance phase 3. Its not perfect but that is how science works . They simply are reevaluating its mechanism as pfizer did with Viagra. From cancer to type two all to SIDD and plus ozempic.
0 · Reply
Rob88ynn
Rob88ynn Oct. 24 at 4:55 PM
$BMEA buy and set an alarm For 12/1/26. Don’t look at it until then
0 · Reply
Patoun
Patoun Oct. 24 at 2:24 PM
$BMEA message to GOBOFUSD I sold a few days ago. So my message is even clearer and more disinterested. I hate your messages. They are almost all dishonest. You change your mind like a shirt, when you have Biomea shares you are ultra positive on the title with price targets between 2.4 and 5 dollars and the next day when you have sold everything you throw garbage endlessly with a price target at almost 0. Stop your smoke and mirror . go back to the stock market sites in France to throw bullshit. We are all fed up with you here, stop your scam. Will not even read you back, blacklisting you now, little crrok
0 · Reply
Ducmanallja
Ducmanallja Oct. 24 at 1:46 PM
$BMEA does this POS ever close Green?
1 · Reply
BobBijawklah
BobBijawklah Oct. 23 at 9:09 PM
$BMEA my logic and price targets line up with option activity. a year and half trading at 3-5 . Two and half 5-7. three and half 7-10.5 years 15-20 dollars a share. Again reference companies like GILD on their first approval how did the price act.
1 · Reply
BobBijawklah
BobBijawklah Oct. 23 at 7:55 PM
$BMEA Icovamenib increases the glp1 recepetors in your beta cells. Ozempic is a glp 1 drug it turbo boosts the a1c reduction. They ran trial and saw great consistent reponses in certain sub groups. Look this is science based factual based data analysis . Icovamenib was administered to all types of diabetic patients. Each group has different causes genetic and non genetic that cause high blood sugar. if you controlled on ozempic then no need for icovamenib. If you are insulin deficient meaning your body does not produce enough insulin naturally then icovamenib works >if you are insulin resistant icovamenib does not work as well as your already producing insulin but your body is not processing it efficiently. If you are not well controlled on ozempic then next step is insulin. Icovamenib works then . And that gives novo a new revenue stream for ozempic as once they go to insulin ozempic stops. And their is a pre diabetes market potential for icovamenib. Fin steal at this price.
0 · Reply
Latest News on BMEA
Biomea Fusion, Inc. - Special Call

Oct 7, 2025, 12:05 PM EDT - 18 days ago

Biomea Fusion, Inc. - Special Call


Stocks to Watch: Biomea Fusion, Bitdeer Technologies

Jun 17, 2025, 7:28 PM EDT - 4 months ago

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

BTDR


Biomea Fusion Announces Leadership Transition

Mar 25, 2025, 7:00 PM EDT - 7 months ago

Biomea Fusion Announces Leadership Transition


nf04
nf04 Oct. 24 at 7:34 PM
$BMEA https://www.wsj.com/market-data/quotes/BMEA/company-people/executive-profile/53552593; https://www.investing.com/equities/pharmacyclics-chart; with all the blame against the management, most seem to forget what about absolute veterans sit at the helm of Biomea; Erdtmann (Pharmacyclics, Ibrutinib, blockbuster in CLL) and Hitchcock (Gilead) were involved in two of the biggest ever Biotech growth stories. They also seem to have taken inspiration of Duggan's approach at Pharmacyclics regarding minimal direct compensation, I think the upcoming earnings report will come in as a decent catalyst.
1 · Reply
BobBijawklah
BobBijawklah Oct. 24 at 7:18 PM
$BMEA light the match
0 · Reply
bet_on_biotechs
bet_on_biotechs Oct. 24 at 6:31 PM
$BMEA Someone told me to take a look here... I did...attending a funeral would have been more fun... Conclusion: The lies here are so high that the beams bend and I wondered why some people are typing their fingers to the bone when nothing is expected in the next few years. Kind of strange... If I were interested, I would think about why that is...just a side note. Short visit ended - nice weekend.
0 · Reply
BobBijawklah
BobBijawklah Oct. 24 at 6:01 PM
$BMEA three years from now mark my previous post and you will be saying marty ....
0 · Reply
BobBijawklah
BobBijawklah Oct. 24 at 5:59 PM
$BMEA Icovamenib was a cancer drug at first. VIagra was a high blood pressure drug at first. All drugs are hypothesis driven . So you must follow the data. hedge funds viewed the data in a narrow lens. td failed to meet the anticipated threshold MNGT was then basing their new trial plans off of a small % of the trial participants based on their anaylsis. Given the need for more raises it became to risky for some and they reversed positions and shorted. Now From all models pre clinical to early clinical the drug has performed the same . So when they complete the bigger trials of SIDD and Ozempic plus that data will bring the stock back to levels pre drop . So buying now is smart because they have enough cash to get to that data. Once they do they will do an offering to advance phase 3. Its not perfect but that is how science works . They simply are reevaluating its mechanism as pfizer did with Viagra. From cancer to type two all to SIDD and plus ozempic.
0 · Reply
Rob88ynn
Rob88ynn Oct. 24 at 4:55 PM
$BMEA buy and set an alarm For 12/1/26. Don’t look at it until then
0 · Reply
Patoun
Patoun Oct. 24 at 2:24 PM
$BMEA message to GOBOFUSD I sold a few days ago. So my message is even clearer and more disinterested. I hate your messages. They are almost all dishonest. You change your mind like a shirt, when you have Biomea shares you are ultra positive on the title with price targets between 2.4 and 5 dollars and the next day when you have sold everything you throw garbage endlessly with a price target at almost 0. Stop your smoke and mirror . go back to the stock market sites in France to throw bullshit. We are all fed up with you here, stop your scam. Will not even read you back, blacklisting you now, little crrok
0 · Reply
Ducmanallja
Ducmanallja Oct. 24 at 1:46 PM
$BMEA does this POS ever close Green?
1 · Reply
BobBijawklah
BobBijawklah Oct. 23 at 9:09 PM
$BMEA my logic and price targets line up with option activity. a year and half trading at 3-5 . Two and half 5-7. three and half 7-10.5 years 15-20 dollars a share. Again reference companies like GILD on their first approval how did the price act.
1 · Reply
BobBijawklah
BobBijawklah Oct. 23 at 7:55 PM
$BMEA Icovamenib increases the glp1 recepetors in your beta cells. Ozempic is a glp 1 drug it turbo boosts the a1c reduction. They ran trial and saw great consistent reponses in certain sub groups. Look this is science based factual based data analysis . Icovamenib was administered to all types of diabetic patients. Each group has different causes genetic and non genetic that cause high blood sugar. if you controlled on ozempic then no need for icovamenib. If you are insulin deficient meaning your body does not produce enough insulin naturally then icovamenib works >if you are insulin resistant icovamenib does not work as well as your already producing insulin but your body is not processing it efficiently. If you are not well controlled on ozempic then next step is insulin. Icovamenib works then . And that gives novo a new revenue stream for ozempic as once they go to insulin ozempic stops. And their is a pre diabetes market potential for icovamenib. Fin steal at this price.
0 · Reply
BobBijawklah
BobBijawklah Oct. 23 at 7:46 PM
$BMEA If i said to you could buy gild in 2001 for under 2 dollars with their first drug approval years away would you buy or would you cave in and sell after a 40% loss. Or if i told you could buy GILD in 2010 for 17.00 dollars a share 2 years before their hep c drug was approved would you? Folks BMEA will make it to 17 per share in next 5 -7 years. 100% positive on that. Look thomas butler is no slouch . He now runs an investment biotech firm and his pics are on. BMEA science is reveolutionary in the aspect it improves the top selling Diabetes drug in the world . So ill hold and stack. And sit back and relax when it flys into the double digits and beyond.
1 · Reply
verusabiz
verusabiz Oct. 23 at 7:42 PM
$BMEA Bought another load, over 22,000 now
0 · Reply
BobBijawklah
BobBijawklah Oct. 23 at 7:38 PM
$BMEA thank you for 1.35 bought me another 1000 shares. Load um up boys may take a few years but i will be dancing in the streets eventually.
0 · Reply
GODOFUSD
GODOFUSD Oct. 23 at 7:37 PM
$BMEA After this conference call, it's clear that they gave no reason for anyone to buy. it's a sell signal. NO PARTNERS = BANKRUPTCY
4 · Reply
GODOFUSD
GODOFUSD Oct. 23 at 7:33 PM
0 · Reply
GODOFUSD
GODOFUSD Oct. 23 at 7:30 PM
$BMEA reading all those ppl say i buy... it sound like the AMC FAM
0 · Reply
abdsamad
abdsamad Oct. 23 at 7:29 PM
$BMEA this Shit giving me heart attack 🥹
1 · Reply
GODOFUSD
GODOFUSD Oct. 23 at 6:59 PM
$BMEA 0.5 is next , only a partnership or privat investment could save this chart. other news wont help
1 · Reply
BC_TRADER
BC_TRADER Oct. 23 at 6:57 PM
$BMEA I liked the call and it's near the bottom. Buying some...
0 · Reply
ATLATL
ATLATL Oct. 23 at 6:50 PM
$BMEA lol
0 · Reply
GODOFUSD
GODOFUSD Oct. 23 at 6:13 PM
$BMEA If $BMEA is stuck below $1.5, it's the result of bad management (2nd dilution)– with better leadership, we’d be above $5!
0 · Reply
GODOFUSD
GODOFUSD Oct. 23 at 6:05 PM
$BMEA Enough with the shit talks here – I’m bullish on $BMEA but not here to save my bags. I’m fighting as a shareholders! We invested for value, not to let management burn cash with dilutions. Good data won’t save bad leadership. We need partnerships or private investment ! without that, the boat will sink
0 · Reply